Last Updated: 14 Nov 2024
Executive Summary
Bellring Brands LLC (BRBR) is a leading manufacturer and seller of nutritional products in the United States and internationally. The company has a strong financial position with a market capitalization of $9.28 billion and an EBITDA of $398.7 million. BRBR's trailing price-to-earnings ratio of 43.24 indicates that the stock is currently trading at a premium to the market. However, the company's forward PE ratio of 28.49 suggests that analysts expect BRBR's earnings to grow in the future.
Company Overview
Bellring Brands LLC is headquartered in Saint Louis, Missouri. The company's products include nutritional supplements, vitamins, minerals, and herbs. BRBR sells its products through a variety of channels, including retail stores, online retailers, and healthcare professionals. The company has a strong brand portfolio that includes the brands Metagenics, Xymogen, and Pure Encapsulations.
Fundamental Analysis
BRBR's financial performance has been strong in recent years. The company's revenue has grown from $1.52 billion in 2019 to $1.91 billion in 2023. BRBR's net income has also grown significantly, from $164.4 million in 2019 to $272.7 million in 2023. The company's profit margin has remained relatively stable at around 11.6%.
BRBR's balance sheet is also strong. The company has $398.7 million in cash and equivalents and $529.5 million in total debt. BRBR's debt-to-equity ratio is 0.63, which is below the industry average.
Technical Analysis
BRBR's stock price has been trending higher in recent months. The stock price is currently trading above its 50-day and 200-day moving averages. The relative strength index (RSI) is also above 50, which indicates that the stock is in a bullish trend.
Short Term Outlook
BRBR's stock price is expected to continue to rise in the short term. The company's strong financial performance and positive technical indicators suggest that the stock is a good investment for investors who are looking for a short-term gain.
Long Term Outlook
BRBR's long-term outlook is also positive. The company's strong brand portfolio and growing demand for nutritional products are expected to drive continued growth in the future. BRBR's stock is a good investment for investors who are looking for a long-term hold.
Analyst Recommendations
Analysts are bullish on BRBR's stock. The consensus rating for the stock is "buy." The average analyst target price for the stock is $69.15, which represents a potential upside of 4.2% from the current price.
